These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. Misof K; Landis WJ; Klaushofer K; Fratzl P J Clin Invest; 1997 Jul; 100(1):40-5. PubMed ID: 9202055 [TBL] [Abstract][Full Text] [Related]
23. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility. Carriero A; Doube M; Vogt M; Busse B; Zustin J; Levchuk A; Schneider P; Müller R; Shefelbine SJ Bone; 2014 Apr; 61():116-24. PubMed ID: 24373921 [TBL] [Abstract][Full Text] [Related]
24. Biomechanical, Microstructural and Material Properties of Tendon and Bone in the Young Oim Mice Model of Osteogenesis Imperfecta. Chretien A; Couchot M; Mabilleau G; Behets C Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077325 [TBL] [Abstract][Full Text] [Related]
25. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893 [TBL] [Abstract][Full Text] [Related]
26. Neurocranial growth in the OIM mouse model of osteogenesis imperfecta. Husain TS; Moore JC; Huston LA; Miller CA; Steele AT; Gonzales LA; Handler EK; Organ JM; Menegaz RA Anat Rec (Hoboken); 2024 Mar; 307(3):581-591. PubMed ID: 37638403 [TBL] [Abstract][Full Text] [Related]
27. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse. Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C Front Genet; 2021; 12():705505. PubMed ID: 34447412 [TBL] [Abstract][Full Text] [Related]
28. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Meganck JA; Begun DL; McElderry JD; Swick A; Kozloff KM; Goldstein SA; Morris MD; Marini JC; Caird MS Bone; 2013 Sep; 56(1):204-12. PubMed ID: 23774443 [TBL] [Abstract][Full Text] [Related]
29. Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine. Matthews BG; Roeder E; Wang X; Aguila HL; Lee SK; Grcevic D; Kalajzic I Bone; 2017 Oct; 103():1-11. PubMed ID: 28600151 [TBL] [Abstract][Full Text] [Related]
30. Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model. Yao X; Carleton SM; Kettle AD; Melander J; Phillips CL; Wang Y Ann Biomed Eng; 2013 Jun; 41(6):1139-49. PubMed ID: 23536112 [TBL] [Abstract][Full Text] [Related]
31. Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta. Saban J; Zussman MA; Havey R; Patwardhan AG; Schneider GB; King D Bone; 1996 Dec; 19(6):575-9. PubMed ID: 8968022 [TBL] [Abstract][Full Text] [Related]
32. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice. Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666 [TBL] [Abstract][Full Text] [Related]
33. The material basis for reduced mechanical properties in oim mice bones. Camacho NP; Hou L; Toledano TR; Ilg WA; Brayton CF; Raggio CL; Root L; Boskey AL J Bone Miner Res; 1999 Feb; 14(2):264-72. PubMed ID: 9933481 [TBL] [Abstract][Full Text] [Related]
34. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Evans KD; Lau ST; Oberbauer AM; Martin RB Bone; 2003 Mar; 32(3):268-74. PubMed ID: 12667554 [TBL] [Abstract][Full Text] [Related]
35. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659 [TBL] [Abstract][Full Text] [Related]
36. Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the Shanas N; Querido W; Oswald J; Jepsen K; Carter E; Raggio C; Pleshko N Appl Spectrosc; 2022 Apr; 76(4):416-427. PubMed ID: 34643134 [TBL] [Abstract][Full Text] [Related]
37. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Grabner B; Landis WJ; Roschger P; Rinnerthaler S; Peterlik H; Klaushofer K; Fratzl P Bone; 2001 Nov; 29(5):453-7. PubMed ID: 11704498 [TBL] [Abstract][Full Text] [Related]
38. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta. Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187 [TBL] [Abstract][Full Text] [Related]
39. Bone material elasticity in a murine model of osteogenesis imperfecta. Mehta SS; Antich PP; Landis WJ Connect Tissue Res; 1999; 40(3):189-98. PubMed ID: 10772540 [TBL] [Abstract][Full Text] [Related]
40. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model. Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]